Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Two loss years in a row NBB
Negative result in 2024 and 2025.
-
Tight liquidity NBB
Cash and receivables cover 2 % of short-term debt in 2025; threshold 65 %.
Financials
Financial year 2025
Oblita Therapeutics from Zoersel, company number BE0832102424, closed financial year 2025 with a result of € -13,569 after tax. For that financial year Oblita Therapeutics recorded a gross margin of € 112,473 and equity of € 33,263. Compared with financial year 2024, the result moved from € -68,701 to € -13,569. The company made a loss. The buffer shrank hard: equity is 77 % below last year. High debts against a small own buffer. The most recent annual accounts were filed with the National Bank of Belgium on August 28, 2026.
€ 33,263
▼ 77% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ -13,569
▲ 80 % less loss than in 2024
Profit after tax over the fiscal year.
€ 2,954
▼ 82% vs 2024
Cash and bank balances on the last day of the fiscal year.
Loss, nothing to pay out
Reserves fell to € -183,563.
Debts at end 2025
None
No bank loans on the last day of the fiscal year.
€ 7,984
▼ 88% vs 2024
Supplier invoices still open on the last day of the fiscal year.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Gross margin | € 22,237 | € -22,510 | € -15,244 | € 112,473 | ▲ € 127,717 |
| Profit after taxes | € 20,628 | € -24,638 | € -68,701 | € -13,569 | ▲ € 55,132 |
| Equity | € 132,158 | € 214,644 | € 145,944 | € 33,263 | ▼ 77% |
| Total debts | € 222,677 | € 234,374 | € 356,302 | € 385,258 | ▲ 8% |
| Cash | € 1,359 | € 74,544 | € 16,724 | € 2,954 | ▼ 82% |
| Retained profit | € -76,655 | € -101,294 | € -169,994 | € -183,563 | ▼ € 13,569 |
| Balance sheet total | € 354,835 | € 449,019 | € 502,246 | € 418,521 | ▼ 17% |
Key figures of Oblita Therapeutics, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to Oblita Therapeutics?
What happened at Oblita Therapeutics in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: loss of € 13,569. filed late Source: NBB ↗
- New establishment in Zoersel. KBO
- Start of the company according to the CBE. KBO
In short
From € 20,628 profit in 2022 to € 13,569 loss in 2025.
Best year ever: 2022, with € 20,628 profit.
A new publication or filing at Oblita Therapeutics? We notify you, reason included.
Follow Oblita TherapeuticsDatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
Behind Oblita Therapeutics is Caroline Jansen.
Directors
According to the 2025 annual accounts
Caroline Jansen
Director
Establishments
Establishment units
Physical locations of this company
Oostmallebaan 87
2980 Zoersel
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 1 companies are registered at this address.
All companies at this address →What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0832.102.424
- VAT number
- BE 0832.102.424
- Registered office
- Oostmallebaan 87, 2980 Zoersel
- Names & denominations
- Oblita Therapeutics
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 20 December 2010
- Peppol
- Active · Active since 11 Dec 2025
- Activities · NACE
Speur- en ontwikkelingswerk op biotechnologisch gebied
Overig speur- en ontwikkelingswerk op natuurwetenschappelijk gebied
Vervaardiging van andere voedingsmiddelen, neg
Markt- en opinieonderzoek
Vervaardiging van geneesmiddelen
Groothandel in farmaceutische en medische artikelen
Detailhandel in drogisterijartikelen en onderhoudsproducten
Activiteiten van reclamebureaus
+10